Coronavirus (COVID-19)
Learn more
Number: NSABP-55
This randomized phase III (Phase III trials are a new treatment that’s worked well in a small number of patients with a this disease) trial studies how well Olaparib works in treating patients with triple-negative breast cancer that has not spread to another place in the body who have completed definitive local treatment and chemotherapy. A triple negative breast cancer diagnosis means that the tumor is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. When the pathologist looks at you cancer specimen under a microscope, estrogen/progesterone receptors and HER2 oncogenes (a gene that has the potential to cause cancer) are the biomarkers that help your physician diagnose your cancer. The tissue specimen is obtained through biopsy or surgery. Olaparib may stop the growth of tumor cells by blocking specific enzymes needed for the maintenance of deoxyribonucleic acid (DNA) repair. DNA is the hereditary /genetic material within your body that carries your own unique genetic code. Olaparib may also enhance the DNA damaging effects of chemotherapy.
Who’s eligible:
Available at: The Hospital of Central Connecticut, MidState Medical Center, and Hartford Hospital.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209